Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Tripos renames itself to Exelgen, expands relationships
December 2007
SHARING OPTIONS:

BUDE, England-Tripos Discovery Research, a wholly owned subsidiary of Richmond, Va.-based Commonwealth Biotechnologies Inc., and a provider of drug discovery chemistry services and small molecule products, has changed its name to Exelgen Ltd. The company has also announced three new relationships with CombinatoRx Inc., Elan Pharmaceuticals Inc. and Schering Plough Corp. in addition to a milestone success with its partner GeminX Biotechnologies Inc. "The new name is a hybrid of the company's real value proposition: 'excellence' in the 'genesis' of new and innovative drug discovery paradigms," says Paul D'Sylva, CEO of Commonwealth. "It was at the heart of our decision to acquire this company and is at the heart of what they deliver to their partners. A new name notwithstanding, Exelgen will continue to provide all of the same high-quality services it has in the past and, as a part of the growing CBI group of companies, will now offer new and cutting-edge technologies in support of preclinical drug discovery."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.